Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Epilepsy × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 353 Glioma 134 Brain Neoplasms 134 Gliosarcoma 119 Astrocytoma 100 Central Nervous System Neoplasms 94 Oligodendroglioma 65 Melanoma 59 Neuroblastoma 37 Medulloblastoma 28 Neoplasms 25 Recurrence 24 Ependymoma 24 Neoplasm Metastasis 23 Sarcoma, Ewing 19 Sarcoma 17 Rhabdomyosarcoma 15 Diffuse Intrinsic Pontine Glioma 15 Ovarian Neoplasms 13 Breast Neoplasms 13 Lymphoma 12 Neuroendocrine Tumors 11 Lung Neoplasms 10 Choroid Plexus Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Small Cell Lung Carcinoma 9 Osteosarcoma 9 Neuroectodermal Tumors, Primitive 9 Optic Nerve Glioma 8 Neuroectodermal Tumors, Primitive, Peripheral 8

Interventions

Sirolimus 4 LY3295668 erbumine 3 Everolimus 3 Medical Marijuana 2 Anticonvulsants 2 ziprasidone 1 perampanel 1 enzalutamide 1 clevidipine 1 brivaracetam 1 Zolpidem 1 Warfarin 1 Vigabatrin 1 Vecuronium Bromide 1 Vancomycin 1 Tranexamic Acid 1 Topotecan 1 Tobramycin 1 Therapeutic Touch 1 Temozolomide 1 TAS-119 1 Surgical Procedures, Operative 1 Sulfasalazine 1 Spironolactone 1 Sevoflurane 1 Sevelamer 1 Saline Solution 1 Rocuronium 1 Registries 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05664464 2024-05-10

GLUGLIO

University of Zurich

Phase 1/2 Recruiting

Epilepsy, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡